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The Editorial on the Research Topic
The Role of the Plasminogen Activating System in Neurobiology
The plasminogen activating system has been well-appreciated for its roles in fibrinolysis and
metastatic cancer for over 30 years. These observations lead to the clinical development of the key
plasminogen activators, namely urokinase (u-PA), and tissue-type plasminogen activator (t-PA)
as thrombolytic agents, initially for myocardial infarction in the mid-1980’s, and a decade later
for use in patients with ischaemic stroke following the approval of tPA (Ninds, 1995). Similarly
various attempts were made to modulate cell surface plasminogen activation in an effort to reduce
metastatic spread with varying success, although various components of this system have become
biomarkers for some malignancies (McMahon and Kwaan, 2015).
While many laboratories continue to work in these classical areas, and with due reason, a
growing list of publications dating from the early 1980’s revealed that the main components of
the plasminogen activating system were expressed in almost all cell types and were regulated
by agonists linked to almost all signal transduction pathways identified (Medcalf, 2007). While
these reports were consistent with a broadening role of the plasminogen activating system in
physiology, other findings also from the early 1980’s reported strong expression of components
of the plasminogen activating system in the central nervous system (Krystosek and Seeds, 1981;
Soreq and Miskin, 1981). While these were largely descriptive studies, and without any clear
connection to conventional fibrinolysis or metastatic cancer, speculation arose as to the role of
the plasminogen activating system in the CNS (Yepes and Lawrence, 2004), particularly given the
fact that the normal brain is devoid of fibrin. A decade or so later, CNS focused reports of activity
dependent expression of t-PA in the brain added substantial fuel to notion of a critical role for t-PA
in normal brain function, with increases in t-PA gene expression in the CNS correlated with long
term potentiation (Qian et al., 1993; Huang et al., 1996); and motor learning (Seeds et al., 1995).
Soon after, reports using t-PA deficient mice provided evidence for surprising neurotoxic effects of
t-PA where t-PA, via plasmin was shown to be necessary to facilitate glutamate-mediated toxicity
in vivo (Chen and Strickland, 1997). These reports were published at about the same time that t-PA
was approved for therapeutic use in patients with ischemic stroke and raised concerns with the
clinical use of t-PA given the fact t-PA administration in ischemic stroke was not risk-free.
It soon became apparent that t-PA was influencing numerous other aspects of brain function
including modulation of memory (Huang et al., 1996) and learning (Seeds et al., 2003) and the
response to drugs of addiction (Pawlak et al., 2005; Bahi and Dreyer, 2008; Maiya et al., 2009).
Another landmark discovery made in the early 2000’s reported a potent effect of t-PA at promoting
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BBB disruption in rodent models of cerebral ischemia (Yepes
et al., 2003), an effect that has since been documented in a subset
of human stroke patients who receive thrombolysis (Kidwell
et al., 2008). This further added to the debate of t-PA as a safe
thrombolytic in patients with ischaemic stroke. The enhancing
effect of t-PA on BBB permeability not only directed many
laboratories to uncover the mechanism behind this (Su et al.,
2008; Niego et al., 2012), but also raised interest in other areas of
brain pathology where BBB integrity was compromised, namely
in traumatic brain injury (TBI, Mori et al., 2001). Initial research
into the role of t-PA at influencing outcome following TBI
resulted in a number of publications supporting the notion that
brain-derived t-PA, as opposed to exogenous t-PA (as in ischemic
stroke), was also promoting BBB permeability and subsequent
deleterious outcome following TBI (Sashindranath et al., 2012;
Su et al.). It soon became apparent that t-PA was indeed a major
modulator of BBB permeability (Niego and Medcalf, 2014), even
under non-ischemic or traumatic conditions (Fredriksson et al.,
2016).
With the realization of these various roles of t-PA in the CNS,
questions arose as to how t-PA was implementing these effects
and how it was being regulated. t-PA modulating agents i.e.,
neuroserpin (Lebeurrier et al., 2005), critical signaling systems
i.e., tyrosine kinase (Su et al., 2008), and Rho kinase pathways
(Niego et al., 2012), and receptors i.e., LRP-1 (Yepes et al., 2003;
Samson et al., 2008), and PDGFRα (Fredriksson et al., 2004) in
the CNS were later identified by various groups to participate in
this new frontier of plasminogen activation biology. Although
these findings pushed the field further, controversy also arose.
Conflicting reports on how t-PA promoted neurotoxicity (Nicole
et al., 2001; Matys and Strickland, 2003; Samson et al., 2008),
or its opposite effect (i.e., neuroprotection) via non-proteolytic
means (Kim et al., 1999), or proteolytically at low concentrations
(Echeverry et al., 2010; Wu et al., 2012) continued to pepper
the literature, particularly in recent years (Yepes). The diverse
reach of the plasminogen activators in the brain also posed the
question as to whether there was a common mechanistic element
behind these various, seemingly unrelated events (Fredriksson
et al., 2016).
This themed issue of Frontiers in Cellular Neuroscience
entitled “The role of the plasminogen activating system in
Neurobiology” contains 12 contributions from key scientists in
this field that includes topics ranging from basic neurobiology,
ischaemic stroke, and TBI. Data is presented to implicate t-PA
in neurovascular development, how parallel protease systems
(i.e., the MMPs) may participate in some aspects of t-PA’s effects
in the CNS, novel approaches to attenuate t-PA mediated BBB
permeability in TBI, and new insights into the biology of the
major brain t-PA inhibitor, neuroserpin. We have endeavored
to cover areas of controversy, particularly in relation to the
purported roles of t-PA at promoting both neurotoxicity and
neuroprotection while at the same time include state-of-the-art
reviews, including the insights as to how the coagulation and
the fibrinolytic systems can modulate the neurovascular unit and
how this can in turn have an impact on the immune response.
This themed issue also includes clinical and basic science
perspectives which are likely to seed further innovation to future
research in this field. At the time of writing this Editorial,
these 12 articles have amassed over 15,000 article views and
nearly 3000 downloads within ∼14 months since publication,
providing clear evidence that this particular topic continues to
be vibrant, appealing, and important. The relatively recent entry
of the plasminogen activator into the field of neurobiology has
certainly been an eye-opener. As technology ultimately advances,
it is almost certain that the subsequent years will not only
uncover novel mechanistic insights into the how the plasminogen
activating system functions in the CNS, but it will also uncover
important roles for this enzyme system in other key areas of
neurobiology.
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